BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29781558)

  • 21. The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease.
    Verbeke F; Siwy J; Van Biesen W; Mischak H; Pletinck A; Schepers E; Neirynck N; Magalhães P; Pejchinovski M; Pontillo C; Lichtinghagen R; Brand K; Vlahou A; De Bacquer D; Glorieux G
    Nephrol Dial Transplant; 2021 Apr; 36(5):811-818. PubMed ID: 31837226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary heme oxygenase-1 as a potential biomarker for early diabetic nephropathy.
    Li Z; Xu Y; Liu X; Nie Y; Zhao Z
    Nephrology (Carlton); 2017 Jan; 22(1):58-64. PubMed ID: 26733347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Early detection by urinary proteome analysis : A new concept in patient management of diabetic nephropathy].
    Beige J; Drube J; von der Leyen H; Pape L; Rupprecht H
    Internist (Berl); 2020 Oct; 61(10):1094-1105. PubMed ID: 32897404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of kidney-related outcomes in patients with type 2 diabetes.
    Jardine MJ; Hata J; Woodward M; Perkovic V; Ninomiya T; Arima H; Zoungas S; Cass A; Patel A; Marre M; Mancia G; Mogensen CE; Poulter N; Chalmers J;
    Am J Kidney Dis; 2012 Nov; 60(5):770-8. PubMed ID: 22694950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High urinary sulfate concentration is associated with reduced risk of renal disease progression in type 2 diabetes.
    van den Born JC; Frenay AR; Bakker SJ; Pasch A; Hillebrands JL; Lambers Heerspink HJ; van Goor H
    Nitric Oxide; 2016 May; 55-56():18-24. PubMed ID: 26952289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential Urinary Proteome Analysis for Predicting Prognosis in Type 2 Diabetes Patients with and without Renal Dysfunction.
    Ahn HS; Kim JH; Jeong H; Yu J; Yeom J; Song SH; Kim SS; Kim IJ; Kim K
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression.
    Critselis E; Lambers Heerspink H
    Nephrol Dial Transplant; 2016 Feb; 31(2):249-54. PubMed ID: 25791724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
    Tonneijck L; Muskiet MHA; Smits MM; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2017 Dec; 19(12):1669-1680. PubMed ID: 28449402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton Pump Inhibitors, Nephropathy, and Cardiovascular Disease in Type 2 Diabetes: The Fremantle Diabetes Study.
    Davis TME; Drinkwater J; Davis WA
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2985-2993. PubMed ID: 28591820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease.
    Yang X; Zhang B; Lu X; Yan M; Wen Y; Zhao T; Li P
    BMC Complement Altern Med; 2016 Jul; 16():246. PubMed ID: 27460780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of urinary type IV collagen with GFR decline in young patients with type 1 diabetes.
    Morita M; Uchigata Y; Hanai K; Ogawa Y; Iwamoto Y
    Am J Kidney Dis; 2011 Dec; 58(6):915-20. PubMed ID: 21763044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of the chronic kidney disease urinary proteomic predictor CKD273 with clinical risk factors of graft failure in kidney allograft recipients.
    Rambabova-Bushljetik I; Metzger J; Siwy J; Dohcev S; Bushljetikj O; Filipce V; Trajceska L; Mischak H; Spasovski G
    Nephrol Dial Transplant; 2022 Sep; 37(10):2014-2021. PubMed ID: 34634117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus.
    Kim NH; Kim KB; Kim DL; Kim SG; Choi KM; Baik SH; Choi DS; Kang YS; Han SY; Han KH; Ji YH; Cha DR
    Diabet Med; 2004 Jun; 21(6):545-51. PubMed ID: 15154937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary monocyte chemoattractant protein-1 and vitamin D-binding protein as biomarkers for early detection of diabetic nephropathy in type 2 diabetes mellitus.
    Shoukry A; Bdeer Sel-A; El-Sokkary RH
    Mol Cell Biochem; 2015 Oct; 408(1-2):25-35. PubMed ID: 26104579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial.
    Joergensen C; Tarnow L; Goetze JP; Rossing P
    Diabet Med; 2015 Mar; 32(3):374-81. PubMed ID: 25307511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-Acetyl-seryl-aspartyl-lysyl-proline is a potential biomarker of renal function in normoalbuminuric diabetic patients with eGFR ≥ 30 ml/min/1.73 m
    Nitta K; Nagai T; Mizunuma Y; Kitada M; Nakagawa A; Sakurai M; Toyoda M; Haneda M; Kanasaki K; Koya D
    Clin Exp Nephrol; 2019 Aug; 23(8):1004-1012. PubMed ID: 30949886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary proteomics for early diagnosis in diabetic nephropathy.
    Zürbig P; Jerums G; Hovind P; Macisaac RJ; Mischak H; Nielsen SE; Panagiotopoulos S; Persson F; Rossing P
    Diabetes; 2012 Dec; 61(12):3304-13. PubMed ID: 22872235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients.
    Kim SS; Song SH; Kim IJ; Kim WJ; Jeon YK; Kim BH; Kwak IS; Lee EK; Kim YK
    Diabetes Metab Res Rev; 2014 Nov; 30(8):736-41. PubMed ID: 24687388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.